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Abstract
p21-Activated kinase 2 (PAK-2) seems to be a regulatory switch between cell survival and cell death signaling. We
have shown previously that activation of full-length PAK-2 by Rac or Cdc42 stimulates cell survival, whereas caspase
activation of PAK-2 to the proapoptotic PAK-2p34 fragment is involved in the cell death response. In this study, we
present a role of elevated activity of full-length PAK-2 in anchorage-independent growth and resistance to anticancer
drug–induced apoptosis of cancer cells. Hs578T human breast cancer cells that have low levels of PAK-2 activity
were more sensitive to anticancer drug–induced apoptosis and showed higher levels of caspase activation of
PAK-2 than MDA-MB435 and MCF-7 human breast cancer cells that have high levels of PAK-2 activity. To examine
the role of elevated PAK-2 activity in breast cancer, we have introduced a conditionally active PAK-2 into Hs578T
human breast cells. Conditional activation of PAK-2 causes loss of contact inhibition and anchorage-independent
growth of Hs578T cells. Furthermore, conditional activation of PAK-2 suppresses activation of caspase 3, caspase
activation of PAK-2, and apoptosis of Hs578T cells in response to the anticancer drug cisplatin. Our data suggest a
novel mechanism by which full-length PAK-2 activity controls the apoptotic response by regulating levels of activated
caspase 3 and thereby its own cleavage to the proapoptotic PAK-2p34 fragment. As a result, elevated PAK-2 activity
interrupts the apoptotic response and thereby causes anchorage-independent survival and growth and resistance to
anticancer drug–induced apoptosis.
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Introduction
Tissue homeostasis requires the coordinated regulation of proliferation,
cell survival, and programmed cell death. Many cancer cells acquire the
capability to evade cell death induced by physiological signals or by
anticancer drugs. The molecular mechanisms for such an increased re-
sistance to programmed cell death are largely unknown, but it seems
that dysregulation of proapoptotic and antiapoptotic signaling path-
ways is involved. Among the signaling molecules that regulate cell
survival and cell death is p21-activated kinase 2 (PAK-2). It is a member
of the PAK family of serine/threonine–specific protein kinases. p21-
Activated kinases are activated in response to different receptor signal-
ing pathways, including growth factor receptors, G-protein–coupled
receptors, and integrin receptors, to regulate cell shape and motility
as well as cell survival, cell growth, and programmed cell death.
The mammalian PAK family consists of six members that are divided
into two groups according to biochemical and structural features [1–3].
Group 1 consists of PAK-1 (α-PAK), PAK-2 (γ-PAK), and PAK-3
(β-PAK). PAK-1 and PAK-3 are tissue-specific with the highest levels
in brain, whereas PAK-2 is ubiquitous. Group 2 consists of the more
distantly related PAK-4, PAK-5, and PAK-6. Groups 1 and 2 have
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distinct biochemical and structural properties and seem to serve differ-
ent cellular functions [3]. Group 1 PAKs can be activated by binding of
active GTP-bound p21 GTPases such as Rac and Cdc42 and through
GTPase-independent mechanisms including binding of bioactive
lipids, protein interaction–dependent translocation, and phosphoryla-
tion by other protein kinases [1,2]. The ubiquitous PAK-2 is unique
among the PAK family; it is also activated through proteolytic cleav-
age by caspases, which generates the constitutively active PAK-2p34
fragment [4–7]. Activated full-length PAK-2 has been shown to stimu-
late cell survival and to protect cells from proapoptotic signals [8]. Sim-
ilar antiapoptotic functions have been shown for PAK-1 and PAK-4
[9–11]. In contrast, cleavage of PAK-2 by caspases and generation of
the constitutively active PAK-2p34 fragment induce a cell death re-
sponse [4,6,12,13]. The opposing effects of full-length PAK-2 and
caspase-activated PAK-2p34 might be explained by differential tar-
geting. Caspase-activated PAK-2p34, but not full-length PAK-2, trans-
locates to the nucleus [12].
Elevated PAK-1 and PAK-2 activity is present in several human
breast cancer cell lines and surgical breast cancer samples [14–16].
Expression of the protein kinase inhibitor domain of PAK-2 inhibits
hyperactive PAK-1 and PAK-2 and suppresses proliferation in MDA-
MB435 cells [14]. Inhibition of PAK-1 by overexpression of a kinase-
deficient mutant decreases motility and invasion of highly invasive
MDA-MB435 human breast cancer cells, whereas overexpression of
constitutively active PAK-1 mutants increase motility, invasion, and
anchorage-independent growth of noninvasive MCF-7 human breast
cancer cells [16,17]. In addition, PAK-2 is among 186 genes that are
differentially expressed in breast cancer cells and normal mammary
epithelial cells and are strongly associated with the risk of breast cancer
metastasis and mortality [18]. Therefore, elevated PAK signaling seems
to contribute to the malignant phenotype of breast cancer.
To characterize the role of elevated PAK-2 activity in breast cancer,
we have generated a conditionally active form of PAK-2 by fusion
with the estrogen receptor hormone–binding domain to avoid arti-
facts resulting from continued expression of an active PAK mutant.
Conditionally active PAK-2 was introduced into Hs578T human
breast cancer cells that have low endogenous PAK-2 activity levels.
Conditional activation of PAK-2 stimulates loss of contact inhibition
and anchorage-independent growth of Hs578T cells. Furthermore,
conditional activation of PAK-2 suppresses cell death of Hs578T cells
in response to the anticancer drug cisplatin and downregulates activa-
tion of caspase 3 and its own caspase cleavage to the proapoptotic
PAK-2p34 fragment. Our results reveal a novel mechanism by which
elevated PAK-2 activity promotes malignant growth and resistance to
apoptosis of human breast cancer cells. This is highly significant be-
cause PAK-2 activity is frequently elevated in human breast cancer.
Materials and Methods
Reagents
The antibody specific for PAK-2 (γPAK-V19) and a C-terminal
antibody that detects PAK-1, PAK-2, and PAK-3 (αPAK-C19) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
bodies for phospho-PAK–2(Thr-402), phospho–PAK-2(Ser-141),
and phospho–PAK-2(Ser-192/197) as well as antibodies for cleaved
caspase 3(Asp-175), cleaved caspase 6(Asp-162), cleaved caspase 7
(Asp-198), cleaved caspase 9(Asp-315), cleaved caspase 9(Asp-330),
and cleaved poly (ADP-ribose) polymerase (PARP) were obtained
from Cell Signaling Technology (Danvers, MA). The antibody for en-
hanced green fluorescent protein (EGFP) Living Colors was from
Clontech (Moutain View, CA). The phospho-histone 2B(Ser-14) anti-
body was fromUpstate Biotechnology (Billerica, MA). The β-actin anti-
body, 4-hydroxy tamoxifen (4-HT), and myelin basic protein were
from Sigma (St. Louis, MO). Secondary antibodies conjugated with
horseradish peroxidase, SuperSignal West Pico chemiluminescence re-
agent, andGelcode Blue Staining Reagent were from Pierce (Rockford,
IL). [γ-32P]ATP was obtained from Perkin-Elmer (Waltham, MA).
Restriction enzymes and T4 DNA ligase were obtained from New
England BioLabs (Beverly, MA). Kits for plasmid DNA isolation
were obtained from QIAGEN (Valencia, CA). TransIT-LT1 trans-
fection reagent was from Mirus (Madison, WI). Hoechst 33342 was
from Molecular Probes (Carlsbad, CA). The CellTiter 96 AQueous
One Solution Cell Proliferation Assay was purchased from Promega
(Madison, WI). The cDNA for the hormone binding domain of the
murine estrogen receptor (ER)was provided byDrs. ZhongdongHuang
and J. Michael Bishop (University of California, San Francisco). The
matched surgical samples of cancer and normal breast tissue were
collected at the Froedert Memorial Lutheran Hospital in Milwaukee,
WI, under a protocol approved by the Human Research Review Com-
mittee of the Medical College of Wisconsin.
Molecular Cloning
pRetro-IRES-Zeo was generated by replacing the EGFP domain of
pRetroIRES-EGFP [12] with a zeocin resistance gene. The hormone-
binding domain of the murine ER was added to the C-terminus of
the constitutively active PAK-2L106F mutant [13] in the pKoz/EGFP
vector [19], and EGFP-PAK-2L106F-ER was subcloned into the
pRetroIRES-Zeo vector. A mutation in the ER domain renders it un-
responsive to estrogen, which is frequently found in fetal bovine serum
added as growth supplements to cell culture media. However, the mu-
tant ER domain is still responsive to the artificial ligand 4-HT [20].
Cell Culture, Transfection, Retroviral Transduction,
and Treatments
Phoenix Ampho packaging cells, Hs578Bst human epithelial cells,
and Hs578T, MCF-7, and MDA-MB435 human breast cancer cells
were obtained from American Tissue Culture Collection (Rockville,
MD). Phoenix Ampho cells were grown inDulbecco’s modified Eagle’s
medium (DMEM; Invitrogen/Life Technologies, Carlsbad, CA), and
Hs578Bst, Hs578T, MCF-7, and MDA-MB435 cells were grown in
DMEM/F12 (Invitrogen/Life Technologies) supplemented with 10%
fetal bovine serum (Hyclone, Logan, UT) and penicillin/streptomycin
(Invitrogen/Life Technologies) at 37°C in a humidified atmosphere
of 5% CO2.
Amphotropic retroviruses were obtained by transient transfection
of the retroviral vector into the packaging cell line Phoenix Ampho
using TransIT-LT1 transfection reagent and OPTI-MEM (Invitrogen/
Life Technologies). The culture medium was replaced at 24 hours
after transfection, and retrovirus-containing medium was collected at
48 hours after transfection and filtered through a 0.45-μm filter.
Hs578T cells were grown to approximately 10% to 20% confluency
in 100-mm culture dishes and then transduced by the addition of 2 ml
of retrovirus-containing medium from packaging cells in the presence
of 4 μg/ml polybrene. The culture medium was replaced at 24 hours
after transfection and culture medium containing 500-μg/ml zeocin
was added at 48 hours to select stable Hs578T cell populations for
pRetroIRES-Zeo-EGFP-PAK-2L106F-ER.
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To analyze loss of contact inhibition, cells were grown to con-
fluency. To activate EGFP-PAK-2L106F, 100 nM 4-HT was added
as indicated, and cells were incubated for indicated periods. To analyze
anchorage-independent growth, cells were seeded in 0.4% soft agar
in DMEM/F12 on top of 0.8% soft agar and covered with another
aliquot of 0.8% soft agar. To activate EGFP-PAK-2L106F, 100 nM
4-HT was added as indicated, and cells were incubated for indicated
periods. Images were acquired with a Nikon Eclipse TE2000-Umicro-
scope (Nikon Instruments, Inc, Melville, NY) and a Roper Scientific
Photometrics CoolSnap ES camera using Metamorph 6.2 software
(Roper Scientific, Tucson, AZ).
Western Blot
For treatment, cells were grown to 70% to 90% confluency and
treated with indicated concentrations of taxol or cisplatin for the
indicated periods. To activate EGFP-PAK-2L106F, cells were in-
cubated with 100 nM 4-HT. Cells were lysed in modified RIPA
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100,
0.25% deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml
leupeptin, 10 μg/ml aprotinin, 50 μM MG-132, 25 mM NaF, 25 mM
β-glycerophosphate, and 200 μM sodium vanadate). Cleared lysates
were prepared by centrifugation for 15 minutes at 12,000g. For acid
extraction of histones, the pellet, which includes the chromatin, was
resuspended in hypotonic lysis buffer (10 mM HEPES, pH 7.9,
10 mM KCl, 1.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride,
10 μg/ml leupeptin, 10 μg/ml aprotinin, 50 μM MG-132, 25 mM
NaF, 25 mM β-glycerophosphate, and 200 μM sodium vanadate),
adjusted to 0.2 M HCl, and incubated on ice for 30 minutes. Ex-
tracted histones were cleared by centrifugation for 15 minutes at
12,000g. Protein concentrations were determined by a Bradford assay
using bovine γ-globulin as a protein standard. Western blots were
performed with cleared lysates (15-30 μg) or acid-extracted histones
(1-2 μg) by sodium dodecyl sulfate (SDS)–polyacrylamide gel electro-
phoresis, transferred onto polyvinylidene membranes, and detected by
chemiluminescence using horseradish peroxidase–conjugated second-
ary antibodies and SuperSignal Pico reagent. X-ray film exposures were
converted into digital images using a Umax scanner (Techville, Inc,
Dallas, TX), and images were processed using Adobe Photoshop 6.0.
In-gel Protein Kinase Assays
In-gel assays were performed with 0.1 mg/ml of myelin basic pro-
tein copolymerized in the separating gel of 11% SDS–polyacrylamide
gels [21]. Cell lysates were prepared as described above. Cell lysates
(30 μg) were separated by electrophoresis in the substrate-containing
gels. After electrophoresis, gels were washed twice for 1 hour in 50 mM
Tris-HCl, pH 8.0, 20% 2-propanol, once for 1 hour in 50 mM
Tris-HCl, pH 8.0, 2 mM 2-mercaptoethanol (buffer A), and dena-
tured twice for 1 hour in buffer A containing 6 M guanidine-HCl at
room temperature. Renaturation was performed with five changes
of buffer A containing 0.04% Tween 40 for 16 to 24 hours at
4°C. Phosphorylation was carried out in 20 mM Tris-HCl, pH 7.4,
10 mM MgCl2, 0.4 mM EGTA, 30 mM 2-mercaptoethanol, and
50 μM [γ-32P]ATP (500 cpm/pmol) for 1 hour at room temperature.
Excess of [γ-32P]ATP was removed by washing in 5% trichloroacetic
acid and 1% sodium pyrophosphate. Gels are stained with Gelcode
Blue, dried, and subjected to autoradiography. X-ray film exposures
were converted into images using a Umax scanner, and images were
processed using Adobe Photoshop 6.0.
Cell Death Assay
Cells were grown to 50% to 70% confluency and treated with
50 nM taxol or 50 μM cisplatin for the indicated periods. To activate
EGFP-PAK-2L106F, cells were incubated with 100 nM 4-HT. Cells
were stained with 10 μg/ml Hoechst 33342 for 10 minutes and
analyzed by fluorescence microscopy. To determine levels of pro-
grammed cell death at least 500 cells were counted and analyzed for
apoptotic chromatin condensation and fragmentation.
Cell Viability Assay
Cell viability in response to stress stimulants was determined with
the CellTiter 96 AQueous One Solution Cell Proliferation Assay.
Quadruplicate cell samples were seeded at 10,000 cells per well in
96-well plates and incubated for 16 to 24 hours. Cells were treated
with 50 nM taxol or 50 μM cisplatin for the indicated periods. To
activate EGFP-PAK-2L106F, cells were incubated with 100 nM
4-HT. Cell viability was measured by addition of the MTS tetrazo-
lium compound. During a 2-hour incubation at 37°C, MTS was
converted to the colored formazan, which was detected at 490 nm
with a plate reader. Background absorbance was corrected by subtrac-
tion of blanks with an equal volume of growth medium. Background
caused by cellular debris was corrected by subtraction of sample ab-
sorbance at the reference wavelength of 630 nm.
Results
Treatment of Human Breast Cancer Cells with the
Anticancer Drugs Cisplatin and Taxol Causes Caspase
Activation of PAK-2 and Cell Death
We have shown previously that caspase activation of PAK-2 in-
duces a cell death response [12]. To examine whether anticancer
drug–induced cell death of human breast cancer cells involves caspase
activation of PAK-2, Hs578T, MDA-MB435, and MCF-7, human
breast cancer cells were treated with cisplatin or taxol, which cause
DNA damage or mitotic arrest, respectively. Cell lysates were ana-
lyzed by Western blot with a C-terminal anti-PAK antibody that
detects PAK-1 and PAK-2 as well as caspase-activated PAK-2p34
(Figure 1). Treatment with cisplatin or taxol resulted in caspase cleav-
age of PAK-2 and generation of PAK-2p34 in Hs578T and MDA-
MB435 cells, but cisplatin was more effective than taxol in generating
PAK-2p34. Treatment with cisplatin but not taxol caused caspase
activation of PAK-2 in MCF-7 cells. Because caspase 3 has been
shown to cleave PAK-2 in vitro [7], we analyzed the activation of
caspase 3 in response to cisplatin and taxol using an antibody specific
for cleaved, active caspase 3. Treatment with cisplatin or taxol re-
sulted in the activation of caspase 3 in Hs578T and MDA-MB435
cells, but cisplatin was more effective than taxol. As expected, treat-
ment with cisplatin or taxol did not cause activation of caspase 3 in
caspase 3–deficient MCF-7 cells [22]. Because caspase activation of
PAK-2 correlates with activation of caspase 3, it seems that caspase 3
is the main caspase that cleaves PAK-2 to the proapoptotic PAK-
2p34 fragment in Hs578T and MDA-MB435 cells. However, the
fact that caspase activation of PAK-2 occurs in caspase 3–deficient
MCF-7 cells in response to cisplatin shows that other caspases are
capable to cleave PAK-2. Caspases 8 and 10 have both been shown
to cleave PAK-2 and generate the PAK-2p34 fragment but to a lesser
degree than caspase 3 [23].
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Because Hs578T, MDA-MB435, and MCF-7 human breast cancer
cells showed more caspase activation of PAK-2 in response to cisplatin
than taxol, we compared the effects of cisplatin and taxol on cell via-
bility and apoptosis of these breast cancer cells (Figure 2). Treatment
with 50 μM cisplatin resulted in a marked reduction of cell viabil-
ity of Hs578T cells at 24 hours and a further decline to almost zero
at 48 hours (Figure 2A). In comparison, MDA-MB435 and MCF-7
cells were relatively less susceptible but showed reduced cell viability
after 48 hours of cisplatin treatment. Treatment with 50 nM taxol re-
duced viability of Hs578T and MDA-MB435 cells at 48 but not at
24 hours, whereas taxol did not reduce viability of MCF-7 cells at 24
or 48 hours (Figure 2B). Histone 2B is phosphorylated at Ser-14 in
response to a variety of apoptotic stimuli in different cell lines. Phos-
phorylation of histone 2B at Ser-14 has been associated with apoptotic
chromatin condensation and cell death [24]. Because histone 2B has
been used as a model substrate of PAK-2, we determined whether
caspase-activated PAK-2p34 phosphorylates histone 2B at Ser-14
and if apoptotic histone 2B phosphorylation correlates with caspase
activation of PAK-2 in response to 50 μM cisplatin or 50 nM taxol
(Figure 2C). Recombinant PAK-2p34 but not kinase-deficient PAK-
2p34K278R phosphorylated histone 2B at Ser-14 in vitro. Fur-
thermore, histone 2B was phosphorylated at Ser-14 in Hs578T and
MDA-MB435 cells in response to the anticancer drugs cisplatin or
taxol. Cisplatin caused markedly more apoptotic histone 2B phos-
phorylation than taxol in Hs578T cells, whereas taxol treatment
caused slightly more apoptotic histone 2B phosphorylation than cis-
platin in MDA-MB435 cells. Apoptotic histone 2B phosphorylation
was not observed in MCF-7 cells that lack caspase 3 and generated
less or no PAK-2p34 in response to 50 μM cisplatin or 50 nM taxol.
Therefore, apoptotic histone 2B phosphorylation correlates with cas-
pase activation of PAK-2 indicating that caspase-activated PAK-2p34
directly or indirectly mediates phosphorylation of histone 2B at Ser-14
in Hs578T and MDA-MB435 cells in response to cisplatin or taxol.
Figure 1. Caspase activation of PAK-2 and activation of caspase 3
in human breast cancer cells in response to the anticancer drugs
cisplatin and taxol. Treatment of Hs578T, MDA-MB435, and MCF-7
human breast cancer cells with (A) 20, 50, and 100 μM cisplatin
or (B) 20, 50, and 100 nM taxol for 24 hours. Adherent and de-
tached cells were harvested and lysed. Cell lysates were analyzed
by Western blot with a C-terminal anti-PAK antibody. Activation of
caspase 3 was determined with an antibody specific for cleaved
caspase 3. Positions of PAK-1, PAK-2, caspase-activated PAK-
2p34, and cleaved caspase 3 are indicated at the right. Equal protein
loading was verified by Western blot with an anti–β-actin antibody,
but late apoptotic cell lysates such as of Hs578T cells with 50 and
100 μM cisplatin showed decreased β-actin levels.
Figure 2. Effects on cell viability and apoptotic histone 2B phos-
phorylation in human breast cancer cells in response to the anti-
cancer drugs cisplatin and taxol. Hs578T, MDA-MB435, and MCF-7
cells were grown in 96-well plates and treated for 24 or 48 hours with
(A) 50 μM cisplatin or (B) 50 nM taxol. MTS assays were performed
with quadruplicate samples and relative cell viability is shown as
mean values and SDs in comparison to viability of cells before treat-
ment, which was set arbitrarily at 1. (C) Purified histone 2B was
incubated with recombinant GST-PAK-2p34 (100 or 20 ng) or kinase-
deficient GST-PAK-2p34K278R (100 ng) for 30 minutes at 30°C in
the presence of Mg2+ and ATP; Hs578T, MDA-MB435, and MCF-7
human breast cancer cells were treated with 50 nM taxol (Tax) or
50 μM cisplatin (Cis) for 24 hours or left untreated as controls (Co),
and histones were acid-extracted from cell lysates. Phosphorylation
of histone 2B (H2B) at Ser-14 was analyzed by Western blot with an
anti–phospho(S14)H2B antibody.
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Caspase Activation of PAK-2 and Activation of the Caspase
Cascade in Human Breast Cancer Cells in Response to
Treatment with the Anticancer Drugs Cisplatin and Taxol
Because caspase activation of PAK-2 correlated with cell death of
Hs578T, MDA-MB435, and MCF-7 human breast cancer cells in
response to the anticancer drugs cisplatin and taxol, we compared
effects of cisplatin and taxol on the activation of the caspase cascade
and caspase activation of PAK-2 in these breast cancer cells (Figure 3).
Cells were treated with 50 μM cisplatin or 50 nM taxol for 0, 8, 16,
24, 32, and 48 hours. Caspase activation of PAK-2 was determined
by Western blot with a C-terminal anti-PAK antibody that detects
PAK-1 and PAK-2 as well as caspase-activated PAK-2p34. Activation
of the initiator caspase 9 and the effector caspases 3 and 7 was de-
termined by Western blot using antibodies specific for cleaved frag-
ments of these caspases and the caspase substrate PARP. In response
to cisplatin, caspase activation of PAK-2 occurred the most rapid and
at highest levels in Hs578T cells, whereas MDA-MB435 cells showed
slower caspase activation of PAK-2 and lower levels of caspase-activated
PAK-2p34, and MCF-7 cells showed very little caspase-activated PAK-
2p34 (Figure 3A). In all three cell lines, levels of caspase-activated PAK-
2p34 sustained up to 32 hours but decreased at 48 hours. In Hs578T
cells, immunoreactive bands appeared above and below PAK-2p34 at
48 hours, but it is unknown if these bands correspond to modified
forms of PAK-2p34.
In Hs578T cells, cisplatin also caused high levels of activated cas-
pases 3 and 7 and of cleaved PARP, a substrate of caspases 3 and 7.
MDA-MB435 cells showed lower levels of activated caspases 3 and
7 and cleaved PARP, and MCF-7 cells also showed lower levels of
activated caspase 7 and cleaved PARP but, as expected, no activated
caspase 3 (Figure 3A). Cisplatin is believed to activate the intrinsic
apoptotic pathway resulting in the formation of the apoptosome
and autocleavage of caspase 9 at Asp-315 [25,26]. Consequently,
we observed autocleaved caspase 9 at the earliest time points and
the highest levels in Hs578T cells, which were most sensitive to cis-
platin. In MDA-MB435 and MCF-7 cells, which were less sensitive to
cisplatin, autocleaved caspase 9 appeared at later time points and at
lower levels (Figure 3A). Caspase 9 is also cleaved at Asp-330 by cas-
pase 3, which has been interpreted as a positive feedback amplification
loop to accelerate apoptosis. However, newer data have shown that
cleavage at Asp-330 does not activate caspase 9 directly but prevents
inhibition of autocleaved caspase 9 by X-linked inhibitor of apoptosis
(XIAP) [26]. Cisplatin induced the highest levels of caspase 9 cleavage
at Asp-330 in Hs578T cells, which also showed high levels of activated
caspase 3 (Figure 3A). In MDA-MB435 cells, which showed lower
levels of caspase 3, levels caspase 9 cleavage at Asp-330 were also lower.
However, MCF-7 cells, which lack caspase 3, showed low but detect-
able levels of caspase 9 cleavage at Asp-330, indicating that another
caspase can cleave caspase 9 at Asp-330 at least to some degree.
In comparison to cisplatin, taxol treatment resulted in less caspase
activation of PAK-2, activation of caspases 3 and 7, cleavage of PARP,
autocleavage of caspase 9 at Asp-315, and cleavage of caspase 9 at Asp-
330 (Figure 3B). Levels of caspase-activated PAK-2p34, activated cas-
pases 3 and 7, PARP cleavage, and cleavage of caspase 9 at Asp-330
were more similar in Hs578T and MDA-MB435 cells in response to
taxol than they were in response to cisplatin. However, the kinetics of
the response was later and more sustained in MDA-MB435 cells than
in Hs578T cells. Treatment with taxol resulted in activated caspase 7
and PARP cleavage but no caspase-activated PAK-2p34 and cleavage
of caspase 9 at Asp-330 in caspase 3–deficient MCF-7 cells (Figure 3B).
Autocleavage of caspase 9 at Asp-315 was not detected in Hs578T
Figure 3. Activation of caspases and caspase activation of PAK-2 in human breast cancer cells in response to the anticancer drugs
cisplatin and taxol. Hs578T human breast cancer cells were treated with (A) 50 μM cisplatin or (B) 50 nM taxol for 0, 8, 16, 24, 32, and
48 hours. Both detached and adherent cells were harvested and combined. Caspase activation of PAK-2 and activation of caspases were
analyzed by Western blot. Caspase activation of PAK-2 was determined with the C-terminal anti-PAK antibody. Activation of caspases 3, 7,
and 9 and cleavage of the caspase substrate PARP were determined with antibodies specific for cleaved fragments of these caspases and
PARP. Positions of PAK-1, PAK-2, caspase-activated PAK-2p34, and cleaved caspases or PARP are indicated at the right. Even protein
loading was verified by Western blot with an anti–β-actin antibody, but late apoptotic cell lysates such as of Hs578T cells at 24, 32,
and 48 hours of cisplatin treatment showed decreased β-actin levels.
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and MCF-7 cells and was barely detectable in MDA-MB435 cells in
response to taxol, suggesting that alternate mechanisms mediate taxol-
induced activation of caspases 3 and 7 and cell death. Therefore, acti-
vation of caspases correlates with caspase activation of PAK-2 and cell
death in response to cisplatin or taxol, and treatment of Hs578T cells
with cisplatin resulted in the highest levels of activated caspases, caspase
activation of PAK-2, and cell death.
Elevated Activity Levels of Full-length PAK-2 Are Present in
Breast Cancer
Elevated protein or activity levels of PAKs have been associated with
the malignant phenotype of cancer cells, and elevated PAK signaling
seems to contribute to malignant growth [14–16,27]. Therefore, we
analyzed full-length PAK-2 activity and protein levels in Hs578Bst nor-
mal breast epithelial cells and Hs578T, MCF-7, and MDA-MB435
breast cancer cells as well as in matched surgical samples of cancer
and normal breast tissue. Activity levels of PAK-2 were analyzed by
in-gel assays using myelin basic protein as a substrate. PAK-2 protein
levels were determinedwith a specific PAK-2 antibody (Figure 4). PAK-2
activity migrated as two bands with approximately 58 and 62 kDa,
which were previously shown to represent PAK-2 using mouse brain
and BALB3T3 fibroblasts [8]. Most of the PAK-2 protein levels cor-
respond to the 62-kDa band, whereas the 58 kDa contains low or un-
detectable protein levels of PAK-2 (Figure 4). Therefore, the 58-kDa
band seems to correspond to highly active PAK-2. This is in agreement
with an earlier report that endogenously active PAK-2 (the article uses
the older nomenclature PAK I) purified from rabbit reticulocytes mi-
grates at 58 kDa [28]. PAK-2 activity was markedly elevated in MCF-7
and MDA-MB435 breast cancer cells compared with Hs578T breast
cancer cells and Hs578Bst normal breast epithelial cells, whereas PAK-2
protein levels were only slightly increased. Most of the surgical breast
cancer samples (2-8) had markedly higher PAK-2 activity levels than
the matched normal breast tissue samples (Figure 4). PAK-2 protein
levels were not significantly increased in the cancer samples. Therefore,
elevated full-length PAK-2 activity levels are present in the breast cancer
cell lines MCF-7 and MDA-MB435 as well as surgical breast cancer
suggesting a role of hyperactive PAK-2 in breast cancer development
and/or progression.
Elevated Full-length PAK-2 Activity Induces Loss of Contact
Inhibition and Anchorage-Independent Growth
To analyze the role of hyperactive PAK-2 in breast cancer, we con-
structed a conditionally active PAK-2 (Figure 5A). The L106F muta-
tion was introduced into the regulatory domain of PAK-2 to release
the autoinhibitory interaction with the catalytic domain and create
the constitutively active PAK-2L106F [13]. The EGFP domain was
added to the N-terminus to facilitate detection. For conditional acti-
vation with 4-HT the hormone-binding domain of the mouse ER [20]
was added to the C-terminus to generate EGFP-PAK-2L106F-ER.
Stable Hs578T cells for expression of EGFP-PAK-2L106F-ER
(Hs578T-EGFP-PAK-2L106F-ER) were generated and the conditional
activation of EGFP-PAK-2L106F-ER was tested after incubation of
Hs578T-EGFP-PAK-2L106F-ER cells in the absence or presence of
100 nM 4-HT for 16 hours. Cell lysates were analyzed by Western
blot with three different anti–phospho-PAK antibodies that specifically
detect autophosphorylated (active) PAK-2 (Figure 5B). Little basal ac-
tivity of EGFP-PAK-2L106F-ER was observed in the absence of 4-HT,
whereas addition of 4-HT resulted in greatly enhanced activity. Total
levels of EGFP-PAK-2L106F-ER were only slightly increased in the
presence of 4-HT.
Addition of 4-HT to confluent Hs578T-EGFP-PAK-2L106F-ER
cells resulted in three-dimensional growth and the formation of foci
(Figure 5C ). In the absence of 4-HT, Hs578T-EGFP-PAK-2L106F-
ER cells continued growing as a monolayer. Parental Hs578T cells in
absence or presence of 4-HT did not form foci and continued grow-
ing as a monolayer. Therefore, elevating activity levels of full-length
PAK-2 by activation of EGFP-PAK-2L106F-ER resulted in loss of
contact inhibition. Furthermore, in the presence of 4-HT, Hs578T-
EGFP-PAK-2L106F-ER cells grew colonies in soft agar within
96 hours, whereas no colonies were visible in the absence of 4-HT
(Figure 5D). Parental Hs578T cells showed no colony growth in the
absence or presence of 4-HT. Therefore, elevating activity levels of
full-length PAK-2 by activation of EGFP-PAK-2L106F-ER resulted
in anchorage-independent growth. Loss of contact inhibition and
anchorage-independent growth typically stimulate the metastatic po-
tential of cancer cells.
Elevated Full-length PAK-2 Activity Stimulates Cell Survival
and Protects from Cell Death in Response to the Anticancer
Drug Cisplatin
To determine whether elevated full-length PAK-2 activity affects
cisplatin-induced cell death, Hs578T and Hs578T-EGFP-PAK-
2L106F-ER cells were treated with cisplatin in the absence or pres-
ence of 4-HT. Treatment with cisplatin resulted in the stimulation of
cell death in parental Hs578T cells in the absence and presence of
4-HT and in Hs578T-EGFP-PAK-2L106F-ER cells in the absence
of 4-HT (Figure 6A). However, activation of EGFP-PAK-2L106F-
ER with 4-HT dramatically reduced levels of cell death. To verify this
effect of activation of EGFP-PAK-2L106F-ER, we also determined cell
viability of parental Hs578T and Hs578T-EGFP-PAK-2L106F-ER
Figure 4. Elevated activity levels of full-length PAK-2 in breast cancer. Activity levels of PAK-2 in human breast cancer cell lines and
surgical human breast cancer samples (C) and matched normal breast tissue samples (N) were analyzed by in-gel assays using 11%
SDS–polyacrylamide gels containing myelin basic protein. Total levels of PAK-2 were analyzed by Western blot with an anti–PAK-2 anti-
body. The positions of activity and protein bands corresponding to full-length PAK-2 (62 and 58 kDa) are indicated at the right.
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Figure 5. Activation of EGFP-PAK-2L106F-ER induces loss of contact inhibition and anchorage-independent growth. (A) The L106F
mutation was introduced into the regulatory domain of PAK-2 to release the autoinhibitory interaction with the catalytic domain. The
EGFP domain was added to the N-terminus to facilitate detection and the hormone-binding domain of the mouse estrogen receptor to
the C-terminus for conditional activation with the ligand 4-HT. (B) Stable Hs578T-EGFP-PAK-2L106F-ER cells were incubated in the
absence or presence of 100 nM 4-HT for 16 hours. Cell lysates were analyzed by Western blot with three anti–phospho-PAK antibodies
that specifically detect autophosphorylated (active) EGFP-PAK-2L106F-ER or an anti-EGFP antibody to detect total EGFP-PAK-2L106F-ER.
(C) Hs578T and Hs578T-EGFP-PAK-2L106F-ER cells were grown to confluency and then further incubated for 48 hours in the absence
or presence of 100 nM 4-HT. Phase contrast pictures are shown for each of the four samples. Higher-magnification phase contrast
and fluorescent pictures are shown for Hs578T-EGFP-PAK-2L106F-ER cells in the presence of 4-HT. (D) Hs578T and Hs578T-EGFP-
PAK-2L106F-ER cells were seeded in soft agar in the absence or presence of 100 nM 4-HT and incubated for 96 hours. Phase contrast
pictures are shown for each of the four samples. Higher-magnification phase contrast and fluorescent pictures are shown for Hs578T-
EGFP-PAK-2L106F-ER cells in the presence of 4-HT.
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cells after treatment with cisplatin for 24 hours in the absence or pres-
ence of 4-HT with a colorimetric viability assay. Cisplatin decreased
cell viability in parental Hs578T cells in the absence and presence
of 4-HT and in Hs578T-EGFP-PAK-2L106F-ER cells in the absence
of 4-HT (Figure 6B). However, activation of EGFP-PAK-2L106F-ER
with 4-HT dramatically stimulated cell viability. Therefore, elevating
activity levels of full-length PAK-2 by activation of EGFP-PAK-
2L106F-ER protects Hs578T cells from cisplatin-induced cell death.
Elevated Full-length PAK-2 Activity Negatively Regulates
Caspase Activation of PAK-2, Activation of Caspase 3, and
Apoptotic Histone 2B Phosphorylation
Cisplatin treatment causes high levels of cell death and caspase ac-
tivation of PAK-2 in Hs578T cells (Figures 1–3), and stabilization of
caspase-activated PAK-2p34 results in stimulation of cell death in
Hs578T cells [12]. Therefore, we examined whether elevated full-
length PAK-2 activity affects caspase activation of PAK-2 in response
to cisplatin. Cell lysates were analyzed by Western blot with a C-
terminal anti-PAK antibody that detects endogenous PAK-1, PAK-2,
and caspase-activated PAK-2p34 as well as recombinant EGFP-PAK-
2L106F-ER and its caspase-cleaved PAK-2p34-ER fragment (Figure 7A).
As observed previously, treatment with cisplatin resulted in caspase
activation of PAK-2 in parental Hs578T cells. The kinetics of the re-
sponse in these experiments were slower than in previous experiments
(Figure 3A), which is likely because of the varying efficacies of dif-
ferent batches of cisplatin. Caspase cleavage of PAK-2 was evident by
decreased levels of full-length PAK-2 and generation of the PAK-2p34
fragment starting at 16 hours of cisplatin treatment (Figure 7A). Only
slightly less caspase activation of PAK-2 was observed with Hs578T-
EGFP-PAK-2L106F-ER cells in the absence of 4-HT. However, acti-
vation of EGFP-PAK-2L106F-ER with 4-HT greatly reduced caspase
activation of PAK-2. In Hs578T-EGFP-PAK-2L106F-ER cells in the
presence of 4-HT, levels of full-length PAK-2 decreased only slightly,
and levels of the PAK-2p34 fragment were markedly decreased com-
pared with parental cells and Hs578T-EGFP-PAK-2L106F-ER cells
in the absence of 4-HT. Interestingly, levels of EGFP-PAK-2L106F-
ER also decreased significantly in response to cisplatin in the absence
of 4-HT but not in the presence of 4-HT (Figure 7A). Unexpectedly,
levels of the PAK-2p34-ER fragment (indicated by the arrowhead
in Figure 7A) did not correlate with the decrease of EGFP-PAK-
2L106F-ER because they were higher in the presence than in the
absence of 4-HT. This indicates that the PAK-2p34-ER fragment is
rapidly degraded in the absence of 4-HT but not in the presence of
4-HT. Similar results were obtained with an antibody for the ER
domain (data not shown). Our results suggest that elevating activity
levels of full-length PAK-2 by activation of EGFP-PAK-2L106F-ER
downregulates caspase activation of PAK-2.
To determine whether activation of EGFP-PAK-2L106F-ER down-
regulates caspase activation of PAK-2 by affecting the activation of cas-
pases, we analyzed the activation of the initiator caspase 9 and the
effector caspases 3 and 7 using antibodies specific for cleaved fragments
of these caspases and the caspase substrate PARP (Figure 7B). In
Hs578T-EGFP-PAK-2L106F-ER cells in the absence of 4-HT, levels
of activated caspase 3 were slightly decreased compared with parental
cells, whereas in the presence of 4-HT, activated caspase 3 was unde-
tectable (Figure 7B). Unexpectedly, levels of activated caspase 7 were
increased in Hs578T-EGFP-PAK-2L106F-ER cells in the absence of
4-HT compared with parental Hs578T cells. In the presence of 4-HT,
levels of activated caspase 7 decreased but were still at higher levels
than in parental Hs578T cells. Levels of cleaved PARP were increased
in Hs578T-EGFP-PAK-2L106F-ER cells in the absence of 4-HT
compared with parental Hs578T cells but decreased to similar levels
as in parental Hs578T cells in the presence of 4-HT (Figure 7B). Be-
cause PARP is a substrate of caspases 3 and 7, the results are consistent
with the differential up- and down-regulation of the activation of
these caspases in Hs578T-EGFP-PAK-2L106F-ER cells. Treatment
of Hs578T cells with cisplatin resulted in activation and autocleavage
of caspase 9 at Asp-315. Levels of autocleaved caspase 9 were increased
Figure 6. Activation of EGFP-PAK-2L106F-ER reduces levels of cell death and stimulates cell survival in response to cisplatin. (A) Hs578T
and Hs578T-EGFP-PAK-2L106F-ER cells were treated for the indicated times with 50 μM cisplatin in the absence or presence of 100 nM
4-HT. Levels of cell death were determined by staining with Hoechst 33342 and analyzing apoptotic chromatin condensation by fluo-
rescence microscopy. At least 500 cells were counted and categorized as normal or apoptotic by absence or presence of chromatin
condensation and/or fragmentation. Levels of cell death are shown as percentages of total cells. P values for differences to parental
Hs578T cells were calculated by Fisher’s exact test. ***P < .001. (B) Hs578T and Hs578T-EGFP-PAK-2L106F-ER cells were grown in
96-well plates and treated for 24 hours with 50 μM cisplatin in the absence or presence of 100 nM 4-HT. MTS assays were performed
with quadruplicate samples, and relative cell viability is shown as mean values and SDs in comparison to viability of cells before treat-
ment, which was set arbitrarily at 1. P values for differences to parental Hs578T cells were calculated by Fisher’s exact test. ***P< .001.
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in Hs578T-EGFP-PAK-2L106F-ER cells in the absence of 4-HT
compared with parental Hs578T cells. In the presence of 4-HT, levels
of autocleaved caspase 9 decreased to levels slightly lower than those in
parental Hs578T cells (Figure 7B). Caspase 9 cleavage at Asp-330 by
caspase 3 also increased in Hs578T-EGFP-PAK-2L106F-ER cells in
the absence of 4-HT compared with parental Hs578T cells. In the
presence of 4-HT, caspase 9 cleavage at Asp-330 decreased to levels
similar to those in parental Hs578T cells. The elevated levels of acti-
vated caspases 7 and 9 in Hs578T-EGFP-PAK-2L106F-ER cells could
be due to a compensation mechanism caused by the basal activity
levels of EGFP-PAK-2L106F-ER in the absence of 4-HT (Figure 5B).
Interestingly, this increase in caspases 7 and 9 activation does not seem
to contribute to cell death because Hs578T-EGFP-PAK-2L106F-ER
cells in the absence of 4-HTshowed similar levels of cisplatin-induced
cell death as parental Hs578T cells and addition of 4-HT decreased
levels of cell death (Figure 6). Our results show that elevated activ-
ity of full-length PAK-2 downregulates activation of caspase 3. Be-
cause PAK-2 is cleaved by caspase 3, it seems that activated full-length
PAK-2 negatively regulates its own cleavage to the proapoptotic PAK-
2p34 fragment.
We have shown that apoptotic histone 2B phosphorylation at Ser-
14 correlates with caspase activation of PAK-2 in response to treatment
of breast cancer cells with taxol or cisplatin and that PAK-2p34 phos-
phorylates histone 2B at Ser-14 in vitro. Because activation of EGFP-
PAK-2L106F-ER reduces levels of PAK-2p34, we analyzed if it also
affects apoptotic histone 2B phosphorylation (Figure 7C). Apoptotic
histone 2B phosphorylation was slightly reduced in Hs578T-EGFP-
PAK-2L106F-ER cells in the absence of 4-HT and was dramatically
reduced in the presence of 4-HT compared with that in parental cells.
The results provide further evidence that PAK-2p34 is likely the pro-
tein kinase that phosphorylates histone 2B at Ser-14 in Hs578T cells
in response to cisplatin.
Discussion
PAK family protein kinases seem to be involved in the development
or progression of human cancer. Elevated PAK-1 and PAK-2 activity
Figure 7. Activation of EGFP-PAK-2L106F-ER regulates caspase activation of PAK-2, activation of caspases, and proapoptotic histone 2B
phosphorylation. Hs578T and Hs578T-EGFP-PAK-2L106F-ER cells were treated with 50 μM cisplatin at indicated times in the absence or
presence of 100 nM 4-HT. Adherent and detached cells were harvested and lysed. (A) Cell lysates were analyzed by Western blot with a
C-terminal anti-PAK antibody. Positions of EGFP-PAK-2L106F-ER, PAK-1, PAK-2, and caspase-activated PAK-2p34 are indicated at the
right; position of the caspase-cleaved PAK-2p34-ER fragment is indicated by the arrowhead. (B) Activation of caspases 3, 7, and 9 and
cleavage of the caspase substrate PARP were determined with antibodies specific for cleaved fragments of these caspases and PARP.
Even protein loading was verified by Western blot with an anti–β-actin antibody, but late apoptotic cell lysates such as those of Hs578T
and Hs578T-EGFP-PAK-2L106F-ER cells in the absence of 4-HT at 24 hours of cisplatin treatment showed decreased β-actin levels. (C)
Histones were acid-extracted from cell lysates. Phosphorylation of histone 2B (H2B) at Ser-14 was analyzed by Western blot with an
anti–phospho(S14)H2B antibody.
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have been associated with human breast cancer and seem to promote a
more invasive and malignant phenotype [14–16]. Interestingly, PAK-2
is among a panel of “invasiveness” genes that have been strongly as-
sociated with breast cancer metastasis and mortality [18]. Metastatic
cancer is typically treated by chemotherapy with drugs that kill cir-
culating cancer cells, but a subset of circulating cancer cells often
escape cell death and become resistant to anticancer drug treatment.
Full-length PAK-2 has been shown to stimulate cell survival and pro-
tect cells from stress-induced cell death, whereas caspase-activated
PAK-2p34 is involved in the cell death response [8,12,13]. Here, we
show that elevated PAK-2 activity causes anchorage-independent sur-
vival and growth as well as resistance to anticancer drug–induced cell
death of human breast cancer cells. It is suggested that active full-
length PAK-2 downregulates levels of active caspase 3 and its own
cleavage to the proapoptotic PAK-2p34 fragment, and thereby restrains
cell death.
Caspase activation of PAK-2 occurs during anticancer drug–induced
cell death of human breast cancer cells and correlates with cell death
and apoptotic histone 2B phosphorylation. In Hs578T cells, caspase
activation of PAK-2 and apoptotic histone 2B phosphorylation corre-
lates with cell death and activation of caspases. Levels of cell death of
Hs578T cells, activation of caspases 3, 7, and 9, and caspase activation
of PAK-2 are higher in response to cisplatin than taxol. Because levels
of activated caspases 3, 7, and 9 are low in response to taxol, it is sug-
gested that taxol-induced cell death involves other caspases or is, at
least in part, caspase-independent. During apoptosis, histone 2B is
phosphorylated at Ser-14, but the extent of phosphorylation varies de-
pending on the cell type and apoptotic stimulus [24]. Caspase-cleaved
Mst1 has been shown to mediate apoptotic histone 2B phosphoryla-
tion, but we have not detected caspase-cleaved Mst1 in Hs578T,
MDA-MB435, and MCF-7 cells treated with cisplatin or taxol (data
not shown). However, apoptotic histone 2B phosphorylation correlates
with levels of caspase-activated PAK-2p34 in Hs578T, MDA-MB435,
and MCF-7 cells treated with cisplatin or taxol, and conditional acti-
vation of EGFP-PAK-2L106F-ER greatly reduces levels of caspase-
activated PAK-2p34 and apoptotic histone 2B phosphorylation in
response to cisplatin. Because PAK-2p34 phosphorylates histone 2B
at Ser-14 in vitro, it is possible that caspase-activated PAK-2p34 di-
rectly mediates apoptotic histone 2B phosphorylation in breast cancer
cells. Alternatively, caspase-activated PAK-2p34 could mediate apop-
totic histone 2B phosphorylation indirectly by stimulation of another
protein kinase.
Cisplatin seems to induce apoptosis through the intrinsic apoptotic
pathway resulting in the formation of the apoptosome and auto-
cleavage of caspase 9 at Asp-315 [25,26]. Activated caspase 9 then
cleaves and activates the effector caspases 3 and 7, which cleave other
cellular proteins including PAK-2 during the execution of apoptosis
[29,30]. Hs578T human breast cancer cells are highly sensitive to
cisplatin, showing rapid and high levels of activation and autocleavage
of caspase 9, activation of caspases 3 and 7, and caspase activation of
PAK-2 and high levels of cell death within 24 hours. Caspase 9 is also
cleaved at Asp-330 in a feedback loop by activated caspase 3. However,
this does not seem to directly activate caspase 9 but rather abrogate
inhibition by XIAP [26,31]. MDA-MB435 and MCF-7 cells are less
sensitive to cisplatin than Hs578T cells and show less activation of
caspases, caspase activation of PAK-2, and a later onset and lower levels
of cell death.
Treatment of Hs578T, MDA-MB435, and MCF-7 human breast
cancer cells with taxol induced lower levels of activated caspases,
caspase-activated PAK-2p34, and cell death than treatment with
cisplatin. However, in MDA-MB435 cells, differences between cis-
platin and taxol treatments were smaller and less pronounced than
in Hs578T and MCF-7 cells. Within the three breast cancer cell
lines, Hs578T is highly sensitive to cisplatin and moderately sensitive
to taxol, MDA-MB435 is moderately sensitive to cisplatin and taxol,
and MCF-7 is moderately sensitive to cisplatin but resistant to taxol.
The lack of caspase 3 does not seem to be the only reason for the
higher resistance of MCF-7 cells against anticancer drug–induced
apoptosis. MCF-7 cells also show very little activation and auto-
cleavage of caspase 9, which is upstream of caspase 3. Introduction
of the caspase 3 gene into MCF-7 cells restored morphologic nuclear
and DNA fragmentation in response to Bax overexpression but did
not change the rate of cell death [32].
Importantly, elevated PAK activity has been reported in human
breast cancer samples and several human breast cancer cell lines.
We have detected elevated PAK-2 activity in seven of eight surgical
human breast cancer samples. In addition, we have detected elevated
PAK-2 activity in MDA-MB435 and MCF-7 human breast cells but
not in Hs578T human breast cancer cells or Hs578Bst human mam-
mary epithelial cells. To examine the role of elevated PAK activity in
cancer development or progression, we have generated a condition-
ally active form of PAK-2 and introduced it into Hs578T human
breast cancer cells with low endogenous PAK activity levels. Condi-
tional activation of EGFP-PAK-2L106F-ER resulted in loss of con-
tact inhibition and anchorage-independent growth. This indicates a
more malignant phenotype because metastatic cancer cells need to
disseminate from the mammary epithelium, survive in circulation,
and grow at distant sites [33–35]. Normal epithelial cells require con-
tacts of integrins with extracellular matrix proteins for survival and
die by anoikis (detachment-induced apoptosis) when they leave the
epithelial layer and become detached from the extracellular matrix.
In contrast, metastatic cancer cells have the ability to survive outside
the epithelial layer independent of these integrin–extracellular ma-
trix contacts [36–39]. PAKs have been shown to mediate survival sig-
nals downstream from integrin–extracellular matrix contacts [40,41].
Therefore, elevated PAK-2 activity may act as a constitutive survival
signal and thereby allow anchorage-independent survival and growth.
Interestingly, conditional activation of EGFP-PAK-2L106F-ER in
Hs578T human breast cancer cells also suppresses cell death induced
by the anticancer drug cisplatin suggesting that stimulated PAK-2
survival signaling blocks anoikis and anticancer drug–induced apop-
tosis. Recent findings support such an antiapoptotic role of elevated
PAK signaling in mammary epithelial cells. Expression of a con-
stitutively active PAK-1 mutant suppresses activation of caspase 3
in detached MCF-10A mammary epithelial cells [42]. In contrast,
dominant-negative PAK-1 mutants reduce the malignant morphology
of three-dimensionally cultured MCF-10A, NeoT, and AT1 cells [43].
Furthermore, elevated integrin-dependent Rac-PAK-1 signaling sup-
ports resistance to taxol-induced apoptosis of three-dimensional acini
of mammary epithelial cells by allowing stress-induced activation of
NF-κB [44]. Inhibition of PAK activity with a dominant-negative
Rac or the protein kinase inhibitor domain of PAK renders mammary
acini sensitive to cell death.
The balance of antiapoptotic full-length PAK-2 and proapoptotic
PAK-2p34 activity seems to regulate cell survival and cell death. Cis-
platin treatment causes caspase activation of PAK-2 and generation
of the proapoptotic PAK-2p34 fragment, but conditional activation
of EGFP-PAK-2L106F-ER greatly reduces levels of caspase-activated
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PAK-2p34. This seems to be the result of suppression of caspase 3
activation because levels of activated caspase 3 are also dramatically
reduced. Interestingly, levels of activated caspase 7 and, to a lesser
degree, caspase 9 autocleavage at Asp-315 and caspase 3–mediated
cleavage at Asp-330 are upregulated in Hs578T-EGFP-PAK-2L106F-
ER cells in the absence of 4-HT. Because EGFP-PAK-2L106F-ER has
basal activity levels, which are higher than those of endogenous PAK-2
in Hs578T cells, the increase of activated caspases 7 and 9 could be a
compensatory effect caused by the continuous presence of moderately
elevated PAK-2 activity. However, increased levels of activated caspases 7
and 9 do not increase levels of cisplatin-induced cell death or apop-
totic histone 2B phosphorylation. These results indicate that elevated
PAK-2 activity suppresses the apoptotic response by diminishing lev-
els of activated caspase 3 independent of activation of caspase 7 or 9.
In summary, our results show that elevated PAK-2 activity sup-
presses apoptosis and causes anchorage-independent survival and
growth of human breast cancer cells (Figure 8). Apoptotic stimuli
such as anticancer drugs or detachment from the extracellular matrix
initiate the intrinsic or extrinsic apoptosis pathways resulting in ac-
tivation of initiator caspases. Elevated PAK-2 activity seems to suppress
the apoptotic response downstream of activation of initiator caspases
by down-regulating activation of caspase 3 and thereby preventing its
own caspase cleavage to the proapoptotic PAK-2p34 fragment. At
this point, it remains unknown whether PAK-2 affects caspase 3 acti-
vation directly or indirectly through other antiapoptotic factors such as
NF-κB and/or inhibitor of apoptosis (IAP) proteins [45,46]. NF-κB
has been shown to mediate elevated Rac–PAK-1 signaling and to in-
duce expression of IAPs [44,45]. Inhibition of detachment-induced
apoptosis results in anchorage-independent survival, which, in the pres-
ence of growth factors, may be sufficient for anchorage-independent
growth. However, elevated PAK-2 activity could stimulate anchorage-
independent growth directly by affecting the growth factor pathway.
Group 1 PAKs have been shown to stimulate ERK-1/2 activation
through phosphorylation of the upstream protein kinases Raf-1 and
MEK-1 [1]. In addition, stimulation of anchorage-independent growth
of MCF-7 human breast cancer cells by overexpression of a constitu-
tively active PAK-1 mutant seems to be mediated by ERK-1/2 [16].
Elevated PAK-2 activity may promote malignant progression through
multiple targets and pathways and, therefore, represents a potential
therapeutic target to prevent metastasis and restore sensitivity to chemo-
therapeutic drugs.
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